98482-30-5Relevant academic research and scientific papers
Novel quinolizidine salicylamide influenza fusion inhibitors
Yu, Kuo-Long,Ruediger, Edward,Luo, Guangxiang,Cianci, Christopher,Danetz, Stephanie,Tiley, Laurence,Trehan, Ashok K.,Monkovic, Ivo,Pearce, Bradley,Martel, Alain,Krystal, Mark,Meanwell, Nicholas A.
, p. 2177 - 2180 (2007/10/03)
A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 μg/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed.
Substituted Benzamides with Conformationally Restricted Side Chains. 1. Quinolizidine Derivatives as Selective Gastric Prokinetic Agents
Hadley, Michael S.,King, Frank D.,McRitchie, Brian,Turner, David H.,Watts, Eric A.
, p. 1843 - 1847 (2007/10/02)
The gastric prokinetic action of metoclopramide may not be primarily due to its dopamine antagonist activity.The present aim was to obtain a selective gastric prokinetic agent lacking dopamine antagonist activity by conformationally restricting the side c
